Adverse events960

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 960

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Initial Evaluation Period: LN Cohort - Ravulizumab	2	38	2
other	Anaemia	Blood and lymphatic system disorders	Initial Evaluation Period: LN Cohort - Placebo	0	19	0
other	Anaemia	Blood and lymphatic system disorders	Initial Evaluation Period: IgAN Cohort - Ravulizumab	0	43	0
other	Anaemia	Blood and lymphatic system disorders	Initial Evaluation Period: IgAN Cohort - Placebo	0	23	0
other	Anaemia	Blood and lymphatic system disorders	Extension Period: LN Cohort - Ravulizumab to Ravulizumab	0	36	0
other	Anaemia	Blood and lymphatic system disorders	Extension Period: LN Cohort - Placebo to Placebo	0	18	0
other	Anaemia	Blood and lymphatic system disorders	Extension Period: IgAN Cohort - Ravulizumab to Ravulizumab	0	42	0
other	Anaemia	Blood and lymphatic system disorders	Extension Period: IgAN Cohort - Placebo to Ravulizumab	0	23	0
other	Leukopenia	Blood and lymphatic system disorders	Initial Evaluation Period: LN Cohort - Ravulizumab	1	38	1
other	Leukopenia	Blood and lymphatic system disorders	Initial Evaluation Period: LN Cohort - Placebo	1	19	1
other	Leukopenia	Blood and lymphatic system disorders	Initial Evaluation Period: IgAN Cohort - Ravulizumab	0	43	0
other	Leukopenia	Blood and lymphatic system disorders	Initial Evaluation Period: IgAN Cohort - Placebo	0	23	0
other	Leukopenia	Blood and lymphatic system disorders	Extension Period: LN Cohort - Ravulizumab to Ravulizumab	0	36	0
other	Leukopenia	Blood and lymphatic system disorders	Extension Period: LN Cohort - Placebo to Placebo	0	18	0
other	Leukopenia	Blood and lymphatic system disorders	Extension Period: IgAN Cohort - Ravulizumab to Ravulizumab	0	42	0
other	Leukopenia	Blood and lymphatic system disorders	Extension Period: IgAN Cohort - Placebo to Ravulizumab	0	23	0
other	Neutropenia	Blood and lymphatic system disorders	Initial Evaluation Period: LN Cohort - Ravulizumab	1	38	1
other	Neutropenia	Blood and lymphatic system disorders	Initial Evaluation Period: LN Cohort - Placebo	1	19	1
other	Neutropenia	Blood and lymphatic system disorders	Initial Evaluation Period: IgAN Cohort - Ravulizumab	0	43	0
other	Neutropenia	Blood and lymphatic system disorders	Initial Evaluation Period: IgAN Cohort - Placebo	0	23	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04564339/events

API reference For AI assistants

Adverse events960

Sources 3

Read this list from software.